Youngmin Oh

Experience

• 

  GC Biopharma (GC녹십자)

  Nov 2017 - Jul 2019

  Investment Associate

  In charge of Strategic Planning and Investment function to capture potential assets in order to provide new business opportunities and seek synergistic effects for the organizations’ overall business. Missions:➢ Conducted market research and screening (50+ assets/year)➢ Performed feasibility analysis including DCF, multiples➢ Involved in TFT in order to set up cell therapy entity called 'ARTIVA Therapeutics' in the U.S. ➢ Assisted senior in all aspects of investment execution (DD, Valuation, NDA, Term sheet, DA) ➢ Reviewed global business opportunities in Healthcare sector via Private Equity Fund➢ Managed investment portfolio [15 companies (Listed / Unlisted)]➢ Conducted Monthly / Quarterly / Annual Investment Report to C-level Show less

• 

  HUGEL

  Jul 2019 - Jun 2021

  Assistant Manager, Business Development

  In charge of Business Development to seek potential assets and acquire through In-licensing, M&A, and Equity Investment in order to enhance the value and become part of new growth engine in Hugel’s future Business.Mission:➢ Conducted market research and investment deal screening (50~100 assets/year)➢ Performed feasibility analysis including market research, competitor analysis, DCF➢ Analysis of new investment opportunities through multiple DB ➢ Assisted senior in all aspects of investment execution (DD, Valuation, NDA,Term sheet, DA) ➢ Reviewed new business opportunities in Medical Aesthetic sector via TIPS(Tech Incubator Program For Start-ups) Show less

• 

  Gradiant

  Jun 2021 - now

  Senior Financial Analyst, BioWG

  Dedicated to investing in companies specializing in cutting-edge pharmaceuticals, digital healthcare, diagnostic technologies, cgt cdmo, drug delivery system, AI drug disovery/development, and AI/Big data analytics.Mission:➢ Lead investment deal review process focusing on innovative companies in the US and KR regions, evaluating 50+ opportunities annually.➢ Executed 7 successful equity investment deals in areas including diagnostics, lipid nanoparticle (LNP) technology, mRNA, AI drug discovery, and target discovery.➢ Conducted fair value assessments for bio subsidiaries, including Gradiant Bioconvergence, ensuring accurate valuation and strategic decision-making.➢ Managed investor relations for subsidiaries, fostering strong relationships and communicating investment opportunities effectively.➢ Collaborated cross-functionally with internal teams to ensure seamless project implementation and achievement of key milestones.➢ Participated in the investment strategy and fund management of a biotech healthcare fund, contributing to the identification and evaluation of promising investment opportunities. Show less